InterVenn
Combines next generation epiproteomics, instrumentation, and deep learning to augment cancer diagnosis, biomarker, and target discovery.
Employees
Enterprise value
$804m—1.2b
Authorizing premium user...
Combines next generation epiproteomics, instrumentation, and deep learning to augment cancer diagnosis, biomarker, and target discovery.